Events

On 29 - 30 October,  RSSL will be exhibiting at Oxford Global 5th Annual Cell and Gene therapy Congress, London.

Over 350 delegates representing leading biotechnology companies, global pharmaceutical organisations, and internationally renowned academic institutions will be present at the congress. There will be over 30 presentations, case studies and panel discussions focussed on Cell & Gene Therapy development and clinical research, the commercialisation of CAR T treatments, and Cell & Gene Therapy bioprocessing and manufacturing strategies.

14 pre-scheduled one to one meetings, exhibition and informal networking opportunities.

PRESENTATION BY DAVID WRIGHT: COMBATING PARTICULATE CONTAMINATION IN BIOLOGICS
 
Day 1 - 29 October 2019
Stream 2 – Upstream Bioprocessing and Analytics, 14.50 – 15.20

Learning Points: The prevalence and type of physical contaminants that arise during the production of protein based therapeutics and parenteral.

Case studies on how such unknown material can be identified and aid the identification of the root cause of contamination.
Investigation in particulate material forming on long term stability and possible causes in biotherapeutics.

David Wright as physicist/ material scientist is technical lead within the microscopy department at RSSL which comprises around twenty scientists from a diverse range of scientific disciplines who combine various microscopy and analytical techniques to aid manufacturers in solving contamination and product formulation issues.

David’s own expertise is diverse. His interest in microscopy originated from the need, in his early research career to relate the mechanical behaviour of connective tissues to their structure and the physical properties of the proteinacious components that comprise these biological materials. He developed a range of bespoke microscope mounted mechanical devices in order to test such materials and their components.

In his later research career David applied electron microscopy and physicochemical techniques extensively to characterize biomaterials he has synthesized himself for hard tissue replacement well as those developed by industrial partners as delivery vehicles for vaccines. He has put this academic experience to commercial use in problem solving across the food and pharmaceutical industry sectors.

Come and meet David and the RSSL team.

Contact us to arrange a meeting.